High IL‐6 content in peripheral blood in patients with advanced non‐small cell lung cancer may contribute to poor anti‐PD‐1 efficacy and short duration of PFS through inducing alterations in the tumor microenvironment. The gene discussed is PDCD1; the disease is neoplasm.